Clinical Trials in Spain / NCT04675294
Active, not recruiting
Phase 2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
NCT04675294 · tracked via the Priya Life Science Spain tracker
Condition(s) studied
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Investigational drug(s) / intervention(s)
evorpacept: IV Q3W
pembrolizumab: IV Q3W
Study summary
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Eligibility
Inclusion Criteria:
* Patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) that is PD-L1 positive (CPS \> 1) and who have not received prior systemic therapy for their advanced disease.
* Adequate bone marrow function.
* Adequate renal and liver function.
* Adequate ECOG performance status.
Exclusion Criteria:
* Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
* Prior treatment with any anti-CD47 or anti-SIRPα agent.
* Prior treatment with anti-PD-1 or PD-L1.
Primary outcome measure(s)
- Objective response rate per RECIST 1.1 — Last randomized patient reaching at least 24 weeks of follow-up
Trial sites (53)
| Facility | City | Region | Status |
|---|---|---|---|
| Hoag Hospital | Irvine | California | |
| University of California San Diego | La Jolla | California | |
| H. Lee Moffitt Cancer Center | Tampa | Florida | |
| Northwest Georgia Oncology Centers | Marietta | Georgia | |
| Rush University Medical Center | Chicago | Illinois | |
| Blessing Cancer Center | Quincy | Illinois | |
| University of Maryland Medical System | Baltimore | Maryland | |
| Massachusetts General Hospital | Boston | Massachusetts | |
| Rutgers Cancer Institute of New Jersey | Newark | New Jersey | |
| Memorial Sloan-Kettering Cancer Center | Long Island City | New York | |
| The Ohio State University | Columbus | Ohio | |
| Oregon Health & Science University | Portland | Oregon | |
| Vanderbilt - Ingram Cancer Center | Nashville | Tennessee | |
| Houston Methodist Cancer Center | Houston | Texas | |
| St. Vincent's | Sydney | New South Wales | |
| Royal Brisbane and Womens Hospital | Brisbane | Queensland | |
| Peter MacCallum Cancer Centre | Melbourne | Victoria | |
| Sir Charles Gairdner Hospital | Perth | Western Australia | |
| Ashford Cancer Centre Research | Windsor Gardens | Australia | |
| Cliniques Universitaires Saint-Luc | Brussels | Belgium | |
| AZ Groeninge | Kortrijk | Belgium | |
| UZ Leuven | Leuven | Belgium | |
| Hamilton Health Sciences - Juravinski Cancer Centre | Hamilton | Ontario | |
| LHSC - Victoria Hospital | London | Ontario | |
| Ottawa Hospital Cancer Centre | Ottawa | Ontario | |
| Princess Margaret Cancer Centre | Toronto | Ontario | |
| VUMC Goederenontvangst | Amsterdam | Netherlands | |
| Universitair Medisch Centrum Groningen | Groningen | Netherlands | |
| National University Cancer Institute | Singapore | Singapore | |
| National Cancer Centre Singapore | Singapore | Singapore | |
| Chungbuk National University Hospital | Cheongju-si | South Korea | |
| Yeungnam University Medical Center | Daegu | South Korea | |
| Chungnam National University Hospital | Daejeon | South Korea | |
| CHA University of Bundang | Gyeonggi-do | South Korea | |
| Gachon University - Gil Medical Center | Incheon | South Korea | |
| Seoul National University Bundang Hospital | Seongnam | South Korea | |
| Korea University Medical Center (KUMC) - Korea University Anam Hospital | Seoul | South Korea | |
| Seoul National University Hospital | Seoul | South Korea | |
| The Catholic University of Korea - Eunpyeong St. Mary's Hospital | Seoul | South Korea | |
| Samsung Medical Center | Seoul | South Korea |
+ 13 more sites — see the full list on the official registry below.
On this site
📄 Keytruda (pembrolizumab) drug profile →More ALX Oncology Inc. trials in Spain
Other trials for the same condition
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Active, not recruiting
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04675294 on ClinicalTrials.gov ↗ ← All trials in Spain